Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
Vladimir LazarNicolas GirardEric RaymondJean-Francois MartiniSusan GalbraithJacques RaynaudCatherine BressonBenjamin SolomonShai MagidiHovav NechushtanAmir OnnRaanan BergerHaiquan ChenAmal Al-OmariSadakatsu IkedaUlrik N LassenMarina SekachevaEnriqueta Felip FontJosep TaberneroGerald BatistAlan SpatzConjeevaram S PrameshPhilippe GirardJean Yves BlayThierry PhilipIoana Berindan NeagoeAngel PorgadorEitan RubinRazelle KurzrockRichard L SchilskyPublished in: JCO precision oncology (2022)
TNM stage, DDPP score, and immune competence status of normal lung are independent prognostic factors in multivariate analysis. Our findings open new avenues for prospective prognostic assessment and treatment assignment on the basis of transcriptomic profiling of tumor and normal lung tissue in patients with NSCLC.